A class action lawsuit has been filed against Replimune Group following the FDA's rejection of its Biologics License Application for the drug RP1 combined with nivolumab. The FDA cited multiple deficiencies in Replimune's clinical trials and found the evidence insufficient for approval. After the FDA's Complete Response Letter was made public on April 10, 2026, Replimune's stock dropped nearly 20%, then plunged an additional 64% after the company acknowledged the FDA's preference for a randomized controlled trial. Investors who bought Replimune securities during the class period have until October 5, 2026, to join the lawsuit. This legal action highlights significant regulatory and financial risks facing the company.
Baidu announced that its Class A ordinary shares listed on the Hong Kong Stock Exchange will be included in the Shanghai-Hong Kong Stock Connect program starting September 7, 2026. This inclusion allows eligible mainland Chinese investors to directly...
Curaleaf Holdings has opened a new cannabis dispensary in Riverview, Florida, marking its 77th location in the state and 178th across the U.S. This expansion reflects Curaleaf's strategy to grow its presence in Florida's fast-growing medical cannabis...
SpaceX's stock currently trades below its first closing price despite a strong IPO debut, with a consensus analyst target price about 48% higher than the current price. Raymond James analyst Brian Gesuale projects a much more optimistic outlook, sett...
Critical Metals has consolidated 92.5% ownership of the Tanbreez heavy rare earths project and secured a 15-year offtake agreement with REalloys. The company has started a 10,000-meter drilling program to better define its resources. Tanbreez stands ...
Xcel Energy declared a quarterly dividend of $0.5925 per share, continuing its streak of annual dividend increases aligned with its 4%-6% raise policy. The company operates as a regulated utility, providing predictable cash flows supported by state-a...
